Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma

Area of Science:

• Neuroimmunology
• Pharmacology
• Oncology

Background:

• Intrathecal rituximab is investigated for central nervous system (CNS) lymphoma.
• The mechanisms of its efficacy, particularly complement activation and drug distribution, require elucidation.

Purpose of the Study:

• To investigate complement activation as a mediator of intrathecal rituximab efficacy.
• To evaluate the pharmacokinetics of intraventricular rituximab in the CNS.

Main Methods:

• Quantified complement C3 and C5b-9 in cerebrospinal fluid (CSF) via ELISA after intraventricular rituximab.
• Determined rituximab concentrations in CSF and serum.
• Developed a three-compartment pharmacokinetic model for intraventricular rituximab disposition.

Main Results:

• Reproducible activation of complement C3 and C5b-9 in CSF post-rituximab administration.
• C3 expression localized to myeloid cells in CNS lymphoma lesions; high baseline C3 activation correlated with poor prognosis.
• A pharmacokinetic model demonstrated rituximab distribution within the neuroaxis.

Conclusions:

• First evidence of C3 activation in the neuroaxis with intraventricular immunotherapy.
• Complement activation may contribute to rituximab efficacy in CNS lymphoma.
• Pharmacokinetic data support rituximab penetration into neural tissue, with implications for optimizing intraventricular immunotherapy delivery and innate immune response modulation.